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Abstract In a phase III study of lansoprazole treatment,
patients with healed or unhealed erosive esophagitis
entered a titrated open-label treatment period and received
lansoprazole for B6 years to assess long-term maintenance
therapy. Doses were adjusted depending on symptom
response. Endoscopy was performed yearly. One hundred
ninety-ﬁve subjects received lansoprazole for \1t o
72 months; most received daily doses of B30 mg. Lan-
soprazole maintained erosive esophagitis remission in 75%
of subjects receiving treatment for B72 months, with
39 subjects experiencing 50 recurrences. Most subjects
(94–95%) had no or mild symptoms of day or night
heartburn at study end, and 77% were asymptomatic at ﬁrst
erosive esophagitis recurrence. The most common treat-
ment-related adverse events included diarrhea (10%),
headache (8%), and abdominal pain (6%), and were mild or
moderate in severity. Long-term lansoprazole is effective
and well tolerated when used to maintain erosive esopha-
gitis remission for B6 years.
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Introduction
Gastroesophageal reﬂux disease (GERD) is a highly pre-
valent condition, affecting 10–30% of the adult population
in Western countries [1] and utilizing signiﬁcant health-
care resources [2]. When left untreated, or when treated
inadequately, GERD can produce a spectrum of potentially
severe complications [3–5]. One such complication is
erosive esophagitis (EE), a chronic and relapsing condition
associated with signiﬁcant impairment in quality of life
(QoL) [6]. Pharmacologic therapy is necessary for healing
and effective control of symptoms in the majority of
patients [7].
Proton pump inhibitors (PPIs) have emerged as highly
effective treatment not only for rapid healing of EE and
maintenance of remission [8], but also for symptomatic
relief and improvement of QoL [9–11]. Within 1 year of
initial healing, however, the majority of patients experience
both EE relapse and recurrence of symptoms [5, 12–18].
These observations indicate that long-term maintenance
therapy with a PPI is warranted to reduce the risk of relapse
and provide continued symptomatic relief [14, 18]. How-
ever, there remains a paucity of data regarding the long-
term ([12 months) use of PPIs in patients with EE, par-
ticularly in the United States.
Lansoprazole has been studied extensively in a number
of acid-related diseases [5], and a growing number of
studies support its safety and clinical efﬁcacy when used
as long-term maintenance therapy to prevent EE relapse
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DOI 10.1007/s10620-009-0769-5[15, 16, 19–23]. In this article, we report the results of the
titrated open-label treatment period of a multicenter study
conducted to evaluate the safety and efﬁcacy of lansop-
razole in the maintenance treatment of EE. The speciﬁc
purposes of this long-term (up to 6 years) clinical trial were
to assess the efﬁcacy of lansoprazole in the prevention of
EE relapse in recently healed patients and to evaluate the
effectiveness of symptom-based dose titration in the man-
agement of EE and its symptoms.
Methods
Study Design
The focus of this article is the titrated open-label treatment
portion of the M94-140 study (sponsored by Takeda Global
Research & Development Center, Inc., Deerﬁeld, IL). This
study was a randomized, parallel-group, multicenter, phase
III study consisting of an 8-week open-label acute treat-
ment period, a double-blind treatment period lasting up to
12 months, and a titrated open-label treatment period of up
to 82 months (Fig. 1). Patients were enrolled at 19 sites
within the US. The titrated open-label period began when
the subject had a recurrence of EE or when they completed
the double-blind treatment phase.
Study Population
The study population included male and female subjects
aged C18 years with endoscopically proven EE (C grade 2;
Table 1) and without coexisting duodenal and/or gastric
ulcer of C3 mm in diameter (within 7 days before initiating
treatment). Subjects with Barrett’s esophagus (but without
dysplastic changes) were eligible to enter the study. Sub-
jects requiring continuous treatment with digoxin or
theophylline-containing drugs were permitted to enroll.
Subjects were excluded from enrollment for any of the
following reasons: evidence of active comorbid illnesses;
laboratory results outside normal limits; receipt of other
investigational drug(s) within 12 weeks before initiating
study medication; treatment with a PPI within 4 weeks
before initiating study treatment; or requirement for more
than occasional use (B10 days per month) of nonsteroidal
anti-inﬂammatory drugs (NSAIDs) or corticosteroids
equivalent to[10 mg/day prednisone.
After completing the acute treatment period, subjects
with healed EE were eligible to participate in the double-
blind treatment period. Subjects who completed the dou-
ble-blind treatment period without relapse, and those who
experienced a recurrence of EE during this phase of the
study, were eligible for inclusion in the titrated open-label
treatment period.
Treatment
Subjects entering the titrated open-label treatment period
without recurrence of EE after completing the double-blind
treatment phase were given lansoprazole 15 mg QD. Sub-
jects who entered the titrated open-label treatment period
due to recurrence of EE began treatment with lansoprazole
30 mg QD for 8 weeks, at which point subjects returned to
the study center for the evaluation of healing visit. Subjects
not healed after 8 weeks had their dose increased until
endoscopic evidence of healing was documented. Once
healing occurred, subjects continued treatment with lan-
soprazole 15 mg QD. During the remainder of the titrated
open-label treatment period, lansoprazole doses could be
titrated upward (based on recurrence of EE and/or symp-
toms) or downward as required. The dose of lansoprazole
was titrated so that subjects received the minimum dose
required to control their symptoms. Subjects received
lansoprazole 30 mg QD for recurrence of EE, regardless of
whether or not the subject had symptoms. Lansoprazole
doses could be divided; however, the total daily dose could
not exceed 120 mg without permission from the Sponsor.
Each dose was to be taken in the morning before breakfast
(unless directed otherwise by the investigator). Protocol-
required visits were scheduled and conducted every
12 months, and a ﬁnal visit was conducted when a subject
ceased participation in the study.
Lansoprazole 30 mg QD 
241 patients 
Lansoprazole 15 mg QD
100 patients
Ranitidine 150 mg BID
106 patients
Lansoprazole titrated dose 
195 patients 
Up to 82 months’ duration  Up to 12 months’ duration  8 weeks’ duration 
Acute treatment period  Randomised double-blind period  Titrated open-label period*  Fig. 1 Study design
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must have been discontinued at least 7 days before the
screening gastrin test, and anticholinergic medications
must have been discontinued before the ﬁrst dose of acute-
treatment lansoprazole. Aspirin B325 mg/day for cardio-
vascular indications was acceptable, and Gelusil
 (Pﬁzer,
NJ, USA) use was permitted for relief of symptoms.
To evaluate treatment compliance, subjects were
required to return all unused study drug at each scheduled
visit. All unused study drug was to be accounted for and
reconciled between the label attachment form and the drug
accountability form.
Assessments
Efﬁcacy
The primary efﬁcacy outcome was the time to recurrence
of EE, as evaluated by endoscopy. Each study visit inclu-
ded an upper endoscopy using a modiﬁed Hetzel-Dent
grading scale (Table 1) to document the presence or
absence of EE.
Secondary efﬁcacy outcomes included changes in the
severity of primary (daytime and/or night-time heartburn)
and secondary (gastroesophageal regurgitation, dysphagia,
painful swallowing, nausea and vomiting, day and night
abdominal pain, belching, fullness/bloating/early satiety,
abdominal distension, anorexia, ﬂatulence/abdominal
rumbling) symptoms, and the number of Gelusil
 tablets
used. Time to recurrence of primary symptoms was also
assessed. The investigator conducted an interview at each
scheduled 12-month visit to determine the severity of
symptoms experienced in the 2 weeks prior to the visit,
assess symptom relief, and establish the number of Gelu-
sil
 tablets taken since the previous visit.
Safety
Safety monitoring throughout the study entailed assessment
of adverse events, vital signs, concurrent medications, and
(if applicable) digoxin and/or theophylline levels at each
scheduled visit. Physical examinations, laboratory assess-
ments (including gastrin), gastric biopsies, and serum
pregnancy tests for female subjects were also conducted at
each 12-month visit.
Ethical Approval and Informed Consent
All subjects were required to understand and sign the
informed consent prior to screening and to understand and
cooperate with study procedures. Prior to initiating any
study procedures, each investigator site was granted
approval by an Institutional Review Board. The study
adhered to the ethical principles stated in the Declaration of
Helsinki (1996 revision) and was conducted in accordance
with Food and Drug Administration guidelines, Guidelines
for Good Clinical Practice governing clinical study con-
duct, and all applicable local regulations.
Statistical Methods
All subjects who took at least one dose of lansoprazole and
had efﬁcacy measurements available were included in the
efﬁcacy analyses. The primary efﬁcacy endpoint was time
to recurrence of EE, which was summarized using life-
table methods. Five subjects who entered the titrated open-
label treatment period unhealed and subsequently had no
documented healing were excluded from the analysis of
recurrence. Conﬁdence intervals (CIs) of 95% for the rates
were obtained using the estimated standard error and
assuming asymptomatic normality. The relationship
between EE recurrence and various factors [age, body mass
index (BMI; [30 or B30), gender, race (white or non-
white), tobacco use, alcohol use, EE grade at enrollment
into the acute phase, as well as healing status, Helicobacter
pylori (H. pylori) status, and symptom status at entry into
the open-label treatment period] was explored using
logistic regression.
Results of primary and secondary symptom assess-
ments were presented as the number of subjects at each
severity level for the symptom. The percentage of sub-
jects remaining asymptomatic (no or mild day/night
heartburn) during therapy was estimated using life-table
methods for subjects who were asymptomatic at open-
label baseline. All subjects who took at least one dose of
lansoprazole were included in the safety analyses.
Adverse events, laboratory variables, and gastric biopsies
were summarized.
SAS version 6.12 on the UNIX system (version 10.2
operating system) was used to perform the statistical
analyses. All tests were two-sided, and P values B0.05
were considered signiﬁcant.
Table 1 Esophagitis grading scale [12]
Grade Description
0 Normal-appearing mucosa by endoscopy
1 Mucosal edema, hyperemia, and/or friability of mucosa
2 One or more erosion(s)/ulceration(s) involving\10% of the
distal 5 cm of the esophagus
3 Erosions/ulcerations involving 10–50% of the distal 5 cm of
the esophagus, or an ulcer measuring 3–5 mm in diameter
4 Multiple erosions/ulcerations involving[50% of the distal
5 cm of the esophagus, or a single large ulcer measuring
[5 mm in diameter
Dig Dis Sci (2009) 54:1693–1701 1695
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Subjects
A total of 195 subjects with a mean age of 50.8 years
entered the titrated open-label treatment phase. The
majority of subjects were male (131/195; 67%) and white
(176/195; 90%), and approximately half were experiencing
recurrence of EE upon entry (102/195; 52%) (Table 2).
Enrollment of subjects into this treatment period began
in February 1996 and ended in December 1997. While
some subjects received lansoprazole for [72 months
(Table 3), the data for this period are sparse; therefore,
cumulative survival analysis rates are presented only
through 72 months. Safety evaluations, however, are pre-
sented for the entire follow-up period and include those
patients treated for[72 months.
Primary reasons for premature discontinuation in 105/
195 (54%) patients included adverse events (18/195; 9%),
personal issues (13/195; 7%), poor compliance (9/195;
5%), treatment with another drug that would interfere with
evaluation of study drug (7/195; 4%), pregnancy (2/195;
1%), and therapeutic failure (1/195; 1%). Fifty-ﬁve (28%)
patients prematurely discontinued because of other reasons,
including closure of study site or patient lost to follow-up.
Two patients discontinued because they required
fundoplication.
Treatment
During the titrated open-label treatment period, lansop-
razole exposure ranged from\1t o[72 months, with 120/
195 (62%) patients receiving treatment for [60 months
(Table 3). Total daily doses of lansoprazole ranged from
B15 mg to 120 mg, but most subjects received daily
doses of B30 mg. Forty-ﬁve subjects received 60 mg or
more of lansoprazole per day at some time during the
open-label period. During the open-label treatment period,
65% (126/195) of subjects increased their dosage from the
maintenance dose (15 mg daily) at least once, either due
to an endoscopically documented relapse of EE or to
alleviate symptoms. At the ﬁnal titration, the total daily
dose was [30 mg of lansoprazole in 19% (37/195) of
subjects. The percentage of patients within each dose
category at the end of each treatment year is presented in
Fig. 2.
Table 2 Subject demographics and baseline
a characteristics
(N = 195)
Parameter Number of subjects
Gender n (%)
Male 131 (67)
Race n (%)
White 176 (90)
Black 13 (7)
Hispanic 6 (3)
Age (years)
Mean (±SD) 50.8 (±13.8)
Minimum–Maximum 20–82
Weight (males)
Mean (±SD) 199.6 (± 33.0)
Minimum–maximum 131–299
Weight (females)
Mean (± SD) 175.5 (30.4)
Minimum–maximum 116–248
Body mass index
Mean (± SD) 29.0 (4.6)
Minimum–maximum 19–45
Erosive reﬂux esophagitis grade at entry into acute phase n (%)
Grade 2 110 (56)
Grade 3 68 (35)
Grade 4 17 (9)
Erosive reﬂux esophagitis grade at entry into open-label phase n (%)
Healed 93 (48)
Grade 0 74 (38)
Grade 1 19 (10)
Unhealed 102 (52)
Grade 2 82 (42)
Grade 3 16 (8)
Grade 4 4 (2)
H. pylori status N (%)
Negative 155 (80)
a At open-label baseline unless otherwise noted
N Number of subjects evaluated; n number of subjects in category; H.
pylori Helicobacter pylori; SD: standard deviation
Table 3 Duration of lansoprazole exposure for all subjects during the
titrated open-label treatment period
Duration of exposure All subjects (N = 195)
n (%)
12 months or less 16 (8.2)
[12–24 months 15 (7.7)
[24–36 months 13 (6.7)
[36–48 months 10 (5.1)
[48–60 months 21 (10.8)
[60–72 months 57 (29.2)
[72 months 63 (32.3)
Duration of the study ranged from\1 month to 72 months
N Number of subjects evaluated; n Number of subjects exposed
during interval
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Maintenance of Healing
Lansoprazole was effective in maintaining remission of EE
in 75% of subjects receiving long-term open-label therapy
(up to 72 months) (Table 4); during the entire titrated open-
label treatment period (up to 82 months), 39 subjects
experienced a total of 50 recurrences of EE. All recurrences
of EE were grade 2. Logistic regression analysis suggested
that healing status (healed vs. unhealed) at open-label
baseline was predictive of EE relapse (odds ratio = 0.46;
95% CI = 0.22, 0.97), with subjects healed at open-label
baseline less likely to relapse during the titrated open-label
treatment period. No other demographic or baseline factors
were found to be predictive of EE recurrence.
When H. pylori status at open-label baseline was con-
sidered, life-table analysis suggested that H. pylori-positive
subjects were more likely to remain healed through
72 months of therapy (85%) than H. pylori-negative
counterparts (73%) (Table 4). However, H. pylori status
was not found to be predictive of EE recurrence in the
logistic regression analysis.
Symptom Assessment
At open-label baseline, 125/194 (64%) and 110/194 (57%)
subjects experienced primary symptoms of daytime or
night-time heartburn, respectively. At the ﬁnal visit, how-
ever, the majority of subjects assessed had no or only mild
symptoms of daytime (175/185; 95%) or night-time
heartburn (174/185; 94%) (Table 5). Most subjects (30/39;
77%) were also asymptomatic at the time of their ﬁrst
recurrence of EE. Life-table analysis showed that 68% of
patients who had no primary symptoms at open-label
baseline would remain asymptomatic through 72 months of
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Table 4 Proportion of subjects remaining healed
a during the titrated open-label (OL) treatment period
Months 0–12 12–24 24–36 36–48 48–60 60–72
All treated subjects (N = 190)
b n = 178 n = 154 n = 126 n = 114 n = 99 n = 64
Remaining healed (%) 93 85 81 80 77 75
95% CI – 80.1, 90.7 75.4, 87.3 73.7, 86.1 70.9, 84.0 67.9, 82.2
H. pylori-positive subjects (n = 39) n = 39 n = 32 n = 27 n = 23 n = 20 n = 14
Remaining healed (%) 97 91 85 85 85 85
95% CI – 81.9, 100.0 72.0, 97.1 72.0, 97.1 72.0, 97.1 72.0, 97.1
H. pylori-negative subjects (n = 151) n = 139 n = 122 n = 99 n = 91 n = 79 n = 50
Remaining healed (%) 92 84 80 79 76 73
95% CI – 77.6, 90.0 73.6, 87.2 71.6, 85.7 68.1, 83.2 64.3, 81.0
a Counted from the ﬁrst day of OL treatment for subjects entering the OL period healed and from the day of healing in the titrated OL treatment
period for subjects who entered unhealed. The subject was considered as remaining healed within the interval if esophagitis remained at grade 0–
1; cumulative interval rates were calculated based on life-table methods, which calculate the rates based on exposure during successive intervals
b Number of subjects considered exposed during the ﬁrst interval (0–12 months) differs from the number of subjects who entered OL treatment
because of patient withdrawal prior to the midpoint of the interval
H. pylori Helicobacter pylori; CI conﬁdence interval
Dig Dis Sci (2009) 54:1693–1701 1697
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remaining asymptomatic was similar between the
H. pylori-positive and H. pylori-negative subjects. Through
72 months of treatment, 72% of H. pylori-positive subjects
were asymptomatic compared to 67% of H. pylori-negative
subjects.
Although not statistically signiﬁcant, a higher proportion
of subjects who were asymptomatic at open-label baseline
remained relapse-free (78/142; 55%) throughout the open-
label period compared with subjects who were symptom-
atic at baseline (64/142; 45%).
Improvements in secondary symptoms (gastroesopha-
geal regurgitation; dysphagia; painful swallowing; nausea
and vomiting; day and night abdominal pain; belching;
fullness/bloating/early satiety; abdominal distension;
anorexia; ﬂatulence/abdominal rumbling) were also noted.
In total, 111/169 (66%) subjects reported overall symptom
improvement compared with open-label baseline, with 169/
183 (92%) subjects experiencing no or mild secondary
symptoms at the ﬁnal visit (Table 5).
Gelusil
 Use
The majority of subjects (179/195; 92%) used Gelusil

during the titrated open-label treatment period. The median
number of Gelusil
 tablets taken per week was 0.5.
Safety
Overall, 69/195 (35%) patients experienced an adverse
event that was considered to be at least possibly related to
the study drug. Most treatment-related adverse events were
self-limiting and did not result in early discontinuation of
treatment. The most common treatment-related adverse
events (i.e., those experienced by at least 5% of subjects)
were mild or moderate in severity and included diarrhea
(19/195; 10%), headache (16/195; 8%), and abdominal
pain (12/195; 6%). One subject died during open-label
treatment (accidental injury), and two subjects died during
the follow-up period (one subject died 432 days after dis-
continuing treatment due to complications of amyotrophic
lateral sclerosis and one subject died approximately
10 months after discontinuing treatment due to cardiogenic
shock secondary to an acute myocardial infarction). All
deaths were considered by the investigator to be unrelated
to the study drug.
Consistent with ﬁndings from other studies investigating
PPIs, gastric body and antral biopsies demonstrated neither
increased severity of chronic gastritis nor progression to
intestinal metaplasia and/or atrophy. At open-label base-
line, 153/179 (85%) of subjects had evidence of chronic
inﬂammation in gastric body biopsies; at the ﬁnal visit,
54% (82/153) of subjects with evidence of chronic
Table 5 Changes in primary and secondary symptom severity from open-label baseline to the ﬁnal visit of the titrated open-label treatment
period
Symptom severity at
open-label baseline n
Symptom severity at the ﬁnal visit of titrated open-label treatment period n
None Mild Moderate Severe Missing
Primary symptoms
Daytime heartburn N = 194 None 69 53 10 2 0 4
Mild 47 28 14 2 0 3
Moderate 51 29 16 5 0 1
Severe 27 18 7 0 1 1
Total 194 128 47 9 1 9
Night-time heartburn N = 194 None 84 70 8 2 1 3
Mild 27 15 9 1 0 2
Moderate 54 33 14 4 0 3
Severe 29 12 13 3 0 1
Total 194 130 44 10 1 9
Secondary symptoms
Overall signs and symptoms N = 193 None 24 13 8 2 0 1
Mild 82 35 38 4 0 5
Moderate 73 23 42 6 0 2
Severe 14 4 6 1 1 2
Total 193 75 94 13 1 10
N Number of subjects evaluated; n number of subjects at severity level
1698 Dig Dis Sci (2009) 54:1693–1701
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153) of which completely resolved], 55/153 (36%) were
unchanged, and 16/153 (10%) were worsened. A total of
152/179 (85%) subjects had evidence of chronic inﬂam-
mation in antral biopsies at open-label baseline, with 83/
152 (55%) subjects showing improvement [of which 13/
152 (9%) showed complete resolution], 60/152 (39%) were
unchanged, and 9/152 (6%) were worsened at the ﬁnal
visit.
Among H. pylori-positive subjects with active gastric
body inﬂammation at open-label baseline, 18/34 (53%)
improved at the ﬁnal visit; 21/32 (66%) with active gastric
antrum inﬂammation improved. In the H. pylori-negative
group, 6/6 (100%) subjects with active gastric body
inﬂammation improved compared to 11/12 (92%) with
active gastric antrum inﬂammation. For H. pylori-positive
subjects with chronic inﬂammation at baseline, improve-
ment was found in 15/38 (39%) of subjects with gastric
body inﬂammation compared with 18/39 (46%) with gas-
tric antrum inﬂammation. In the H. pylori-negative group,
67/115 (58%) with chronic gastric body inﬂammation
improved compared with 65/113 (58%) with gastric antrum
inﬂammation.
Intestinal metaplasia in the gastric body and antrum was
present in 3% and 22% of subjects, respectively, at one or
more visits during the titrated open-label treatment period.
Atrophy in the antrum and gastric body was seen in a
minority of subjects [5.6% (11/195) and 1.5% [3/195],
respectively] and showed no signiﬁcant increase during the
course of the study. There were no subjects with endocrine
cell dysplasia or neoplasia; however, as expected, endo-
crine hyperplasia (four simple, two linear or micronodular)
associated with PPI-induced hypergastrinemia was
observed in six subjects at the ﬁnal visit.
Discussion
The results of this study demonstrate the long-term efﬁcacy
and safety of lansoprazole treatment for maintenance of EE
remission. Symptom-based lansoprazole dose titration
provided sustained remission of EE in 75% of subjects for
up to 72 months; healing status (healed or unhealed) at
open-label baseline was identiﬁed by multiple logistic
modeling as an important predictive factor for EE recur-
rence. No other demographic or baseline factors were
found to be signiﬁcant predictors of EE relapse. Most
subjects also experienced substantial improvements in
primary and secondary symptoms, and analyses using life-
table methodology suggested that 68% of subjects who had
no primary symptoms at open-label baseline remained
asymptomatic through 72 months of lansoprazole treat-
ment. However, subjects with symptoms present at open-
label baseline were more likely to relapse throughout the
maintenance period–an observation that may have impor-
tant clinical implications, as a lack of symptoms might
predict a lack of EE recurrence.
Lansoprazole was generally well tolerated. As can be
expected in a study of up to 6 years’ duration, a relatively
high proportion of patients (35%) experienced treatment-
related adverse events; however, most such events were
mild or moderate in severity, and the most commonly
experienced events were consistent with those previously
reported in trials assessing lansoprazole use.
Numerous studies have assessed the efﬁcacy of main-
tenance PPI therapy (esomeprazole, lansoprazole,
omeprazole, pantoprazole, and rabeprazole) in patients
with EE. One meta-analysis included 22 randomized con-
trolled trials (RCTs) in which healing and maintenance PPI
doses were compared for efﬁcacy in maintaining EE
remission; a total of 5,964 patients were analyzed, 1,527
(30%) of whom presented with initially severe EE. Healing
doses were generally deﬁned as the standard dose recom-
mended by the manufacturer, while maintenance doses
were deﬁned as half the standard dose. At the end of fol-
low-up, which ranged from 24 to 52 weeks, the frequency
of EE relapse was signiﬁcantly lower among patients
treated with a healing dose of a PPI [relative risk
(RR) = 0.63; 95% CI 0.55–0.73] [8].
The same meta-analysis evaluated 18 RCTs that com-
pared maintenance with healing doses of PPIs in
maintaining symptom relief. A total of 5,116 patients were
assessed, with a follow-up period of 26–52 weeks. The
percentage of patients experiencing symptom recurrence
was signiﬁcantly lower for those treated with a healing
dose of a PPI than for those receiving maintenance doses
(RR = 0.78; 95% CI 0.68–0.88) [8]. These results led to
the suggestion that PPIs taken at a standard dose for a
period of 6 months to 1 year may be more effective than
lower maintenance doses in preventing EE relapse and
recurrence of symptoms [24]. In contrast, the current study
provides evidence that maintenance treatment with lan-
soprazole at doses lower than the standard dose of 30 mg
may be highly effective at maintaining EE remission and
preventing symptom recurrence for up to 6 years.
Throughout the course of the current study, 65% (126/
195) of the subjects did increase their lansoprazole dose
from the maintenance dose (15 mg daily) at least once,
either due to an endoscopically documented relapse of EE
or to alleviate symptoms. However, this is perhaps not
surprising, as the study population included predominantly
H. pylori-negative patients who had high BMIs and a high
risk for recurrence of esophagitis and EE symptoms. Fur-
thermore, the use of higher-than-maintenance doses for
continuous maintenance treatment has been supported by a
meta-analysis from Donnellan and colleagues, who found
Dig Dis Sci (2009) 54:1693–1701 1699
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at preventing EE relapse than maintenance doses [8].
Several published studies have investigated the efﬁcacy
of long-term lansoprazole in maintaining remission of EE
and its symptoms [15, 16, 19–23], yet only one study to
date has assessed lansoprazole maintenance therapy for
more than 12 months [21]. In this study, 73 subjects with
EE were treated with lansoprazole 30 mg and followed for
5 years; 86% remained in remission at the end of the study
[21]. The titrated open-label treatment phase of the current
study has the advantage of a larger patient population
(n = 195) and a longer follow-up period (up to 6 years),
and is unique in its use of symptom-based dose titration.
Our results also suggest that H. pylori-positive subjects
tended to have a greater likelihood of remaining healed
throughout the study duration than their H. pylori-negative
counterparts (85% and 73%, respectively). The higher rates
of EE remaining healed in H. pylori-positive subjects may
be attributable to the observation that H. pylori enhances
the acid-suppressive effects of PPIs, thus raising intragas-
tric pH to a higher level. The mechanism for this
phenomenon remains to be elucidated, but may involve H.
pylori-induced corpus gastritis, which impairs parietal cell
function [25]. However, the percentage of subjects who
were asymptomatic at the end of the study was similar in
the H. pylori-positive and -negative groups.
One weakness of the current study is its open-label
design with lack of a comparator. However, this study is
unique in that symptom-based dose titration was used; it
also had a longer duration than similar trials, and so pro-
vides a more accurate reﬂection of clinical practice in the
context of a real-world setting. Similarly, though most
subjects used Gelusil
 for symptom relief, the median
number of weekly tablets used was low (0.5). Given the
high relapse rate associated with discontinuation of PPI
therapy [5, 13, 14, 17, 18], our ﬁndings enhance and
strengthen the literature supporting the tolerability and
clinical effectiveness of long-term lansoprazole in main-
taining healing and symptom control of patients with EE.
In conclusion, long-term lansoprazole treatment effec-
tively maintains EE remission and controls symptoms. It is
well-tolerated when used for up to 6 years.
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